Jazz Pharmaceuticals plc

Phase 3 AI-extracted

zanidatamab

HER2+ 1L gastroesophageal adenocarcinoma

Resolved

7days ago

Phase 3 readout · ~ Jun 30, 2026 estimated

What's at stake Phase 3 trial results for zanidatamab in HER2+ 1L gastroesophageal adenocarcinoma are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 13h ago

“Zanidatamab sBLA submission for 1L GEA in 1H26 Full-year commercial sales Identifying and Potential approval in 1L GEA late 2026 pursuing opportunities EmpowHER-BC-303 trial top-line in Rare Disease to drive Full-year commercial sales1 in r”

Add to calendar Post on X Reddit

Provenance